Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: As androgens play an essential role in prostate cancer, we sought to develop a real‐time PCR to characterize mRNA expression profiles of human members of the Aldo‐Keto Reductase (AKR) 1C gene family, as well as of 5α‐steroid reductase Type II (SRD5A2) in prostate cancer samples. Functional activity and regulation of AKR1C2, a 3α‐hydroxysteroid dehydrogenase (HSD) type III, was also assessed in prostate cancer cell lines. METHODS: Gene specific PCR primers were established and relative gene expression of human AKR1C family members was determined in paired samples of cancerous and surrounding unaffected prostate tissue. RESULTS: AKR1C2 preferentially reduces DHT to the weak metabolite 5α‐androstane‐3α,17β‐diol (3α‐diol) without conversion of 3α‐diol to DHT in the PC‐3 cell line, and its expression was increased by DHT treatment in LNCaP cells. Selectively reduced expression of AKR1C2 mRNA, but not AKR1C1 (97% sequence identity), was found in approximately half of the pairs whereas AKR1C3 relative expression was not significantly altered. No aberrant expression of AKR1C4 expression or significant differences in SRD5A2 gene expression were found. CONCLUSIONS: AKR1C2 functions as a DHT reductase in prostate‐derived cells lines and is regulated by DHT. Additional studies are needed to further define the significance of reduced AKR1C2 expression in prostate cancer and its potential role in modulating local availability of DHT. Prostate 54: 275–289, 2003. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PENNING, T. M., BURCZYNSKI, M. E., JEZ, J. M., HUNG, C.-F., LIN, H.-K., MA, H., MOORE, M., PALACKAL, N., & RATNAM, K. (2000) · Biochemical Journal · doi:10.1042/bj3510067 · Cited by 649
Molecular genetics of steroid 5 alpha-reductase 2 deficiency
Thigpen, A. E., Davis, D. L., Milatovich, A., Mendonca, B. B., Imperato-McGinley, J., Griffin, J. E., Francke, U., Wilson, J. D., & Russell, D. W. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115954 · Cited by 422
Labrie, F., Luu-The, V, Lin, S., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., & Belanger, A. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0250001 · Cited by 278 · cited 1×
“The local synthesis and metabolism of androgens within the prostate has been referred to as intracrinology [16,17].”
BackgroundLin, H.-K., Jez, J. M., Schlegel, B. P., Peehl, D. M., Pachter, J. A., & Penning, T. M. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.13.0026 · Cited by 194
Khanna, M., Qin, K.-N., Wang, R. W., & Cheng, K.-C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.34.20162 · Cited by 174
Pelletier, G., Luu-The, V., Tětu, B., & Labrie, F. (1999) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549904700602 · Cited by 88
Tchernof, A., Lévesque, É., Beaulieu, M., Couture, P., Després, J., Hum, D. W., & Bélanger, A. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00709.x · Cited by 50
Cited by
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Mostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S., Matsumoto, A. M., Nelson, P. S., & Montgomery, R. B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0728 · Cited by 588
The Aldo-Keto Reductase Superfamily and its Role in Drug Metabolism and Detoxification
Barski, O. A., Tipparaju, S. M., & Bhatnagar, A. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530802431439 · Cited by 542
Aldo-Keto Reductases and Bioactivation/Detoxication
Jin, Y., & Penning, T. M. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105337 · Cited by 383
Metadata
- Authors
- Ji, Q., Chang, L., VanDenBerg, D., Stanczyk, F. Z., & Stolz, A.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2003-01-17
- Volume
- 54
- Issue
- 4
- Pages
- 275-289
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2123728867
- Cited by
- 85
- References
- 7
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. https://app.cochat.ai/papers/10.1002/pros.10192
- The paper
- Ji, Q., Chang, L., VanDenBerg, D., Stanczyk, F. Z., & Stolz, A. (2003). Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. The Prostate. https://doi.org/10.1002/pros.10192
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.